Interestingly, migraine patients had a higher risk of getting diagnosed at stage II or III breast cancer than at stage I. Further, while 365 of 440 women were treated with hormonal therapy, mostly aromatase inhibitors (47.4%) and tamoxifen (35.9%), researchers detected no influence of the hormonal therapy on the course of migraine. This evidence concerns the gene CYP19A1 and migraine disorder.